Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOG3
- Development stage
- Preclinical
- Lead developer
- Mogrify
- Modality
- Gene Therapies
- Administration
- Injection
01
Overview
MOG3 is an experimental in vivo direct cellular reprogramming therapy being developed by Mogrify for the treatment of Type 1 Diabetes. The therapy utilizes the proprietary MOGRIFY® platform to identify the optimal combination of transcription factors required to convert endogenous mature cells into functional, insulin-producing beta-like cells. These transcription factors are delivered in vivo using a viral vector, effectively functioning as a gene therapy to restore lost or degenerate cell populations without the need for stem cell intermediates or ex vivo cell manipulation. The program is currently in the preclinical stage, focusing on establishing proof-of-concept for cell identity conversion within the pancreas.
Beyond the preview
Go deeper on MOG3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOG3.